Docetaxel-related interstitial pneumonitis.
Docetaxel-related interstitial pneumonitis.
复制标题
DOI：
10.2147/tcrm.s90488
复制
发表时间：
2015
影响因子：
2.8
通讯作者：
Chang CY
中科院分区：
文献类型：
--
作者：
Wang CJ;Chang HT;Chang CY
多西他赛（Taxotere®）是一种适用于治疗局部晚期或转移性非小细胞肺癌患者的药物。近年来，在多项病例系列研究中报告了紫杉醇相关间质性肺病（ILD）。ILD发生在多西他赛给药后约10-20天（中位时间：18天）。在此，我们报告了一例患者在使用相对低剂量多西他赛给药后3天内发生ILD肺毒性的病例。尽管一些文章描述了进展为呼吸衰竭并需要插管的患者，但该患者对类固醇治疗反应良好，并停止多西他赛给药。
Docetaxel (Taxotere®) is an agent that is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer. In recent years, docetaxel-related interstitial lung disease (ILD) has been reported in several case series studies. The onset of ILD occurred ~10–20 days (median time: 18 days) after docetaxel administration. Here, we reported the case of a patient who had pulmonary toxicity of ILD within 3 days after using a relatively low-dose docetaxel administration. Although some articles have described patients who progressed to respiratory failure and needed intubation, this patient responded well to steroid treatment and discontinued docetaxel administration.